Abstract Body

Despite the effective diagnostic & therapeutic tools available to eliminate hepatitis C, WHO reported that only 5M people with HCV, out of 71 million infected, had received treatment by the end of 2017. Of these, 2.5M people were treated in Egypt, 1.8M in high-income countries, and a tiny fraction (0.7M) in the rest of the world. In Egypt, a 2018 campaign aimed to screen 53M people and treat 2.2M HCV patients. This is facilitated by locally produced DAAs priced below 1% of the US price, following government rejection of DAA patents. After agreements signed between DAA patent holders and generic manufacturers, DAA prices decreased spectacularly by over 99%, from $120,000 in 2013 to $20 for 12 weeks of the same curative treatment. However, most low-and-middle-income countries eligible for the lowest generic DAA prices end up paying $ 750-1,000, which does not support test and treat strategies. High- and middle-income countries excluded from licensing agreements used different strategies to decrease DAA prices and implement elimination programs. In Brazil, the threat of patent rejection and local DAA production initiatives supported government pricing negotiations, resulting in the lowest prices offered by originator companies. The Malaysian government opted to grant a compulsory license to import affordable generic sofosbuvir at $237 per course, compared to $11,200 with sofosbuvir. Australia paved the way with “Netflix” type agreements aimed at reduced prices based on volumes to support test and treat programs. As demonstrated by countries on track for HCV elimination, the main challenges are detecting the 80% of people unaware of their status and providing universal access to DAAs, essential to halt HCV transmission. Simplification of HCV models of care and DAA affordability are key determinants for countries to launch elimination programs.